Drug Type Small molecule drug |
Synonyms (2R)-2-acetylamino-3-sulfanylpropanoic acid, (R)-2-acetylamino-3-mercaptopropanoic acid, (R)-mercapturic acid + [46] |
Target |
Action inhibitors |
Mechanism Free radicals inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (14 Sep 1963), |
RegulationOrphan Drug (United States), Orphan Drug (European Union) |
Molecular FormulaC5H9NO3S |
InChIKeyPWKSKIMOESPYIA-BYPYZUCNSA-N |
CAS Registry616-91-1 |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Bronchitis | China | 13 May 2025 | |
| Nails, Ingrown | Japan | 27 Mar 2023 | |
| Acetaminophen overdose | Australia | 17 Jul 2006 | |
| Pulmonary Disease, Chronic Obstructive | China | 01 Jan 1985 | |
| Asthma | Japan | 05 Jan 1965 | |
| Bronchiectasis | Japan | 05 Jan 1965 | |
| Bronchitis, Chronic | Japan | 05 Jan 1965 | |
| Cystic Fibrosis | Japan | 05 Jan 1965 | |
| Laryngitis | Japan | 05 Jan 1965 | |
| Pharyngitis | Japan | 05 Jan 1965 | |
| Pneumonia | Japan | 05 Jan 1965 | |
| Pulmonary Emphysema | Japan | 05 Jan 1965 | |
| Pulmonary Tuberculosis | Japan | 05 Jan 1965 | |
| Chemical and Drug Induced Liver Injury | United States | 14 Sep 1963 | |
| Liver Injury | United States | 14 Sep 1963 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Acute Bronchitis | Phase 3 | China | 21 Jun 2019 | |
| Acute Bronchitis | Phase 3 | China | 21 Jun 2019 | |
| Idiopathic Pulmonary Fibrosis | Phase 3 | Belgium | 01 Mar 2000 | |
| Idiopathic Pulmonary Fibrosis | Phase 3 | France | 01 Mar 2000 | |
| Idiopathic Pulmonary Fibrosis | Phase 3 | Germany | 01 Mar 2000 | |
| Idiopathic Pulmonary Fibrosis | Phase 3 | Italy | 01 Mar 2000 | |
| Idiopathic Pulmonary Fibrosis | Phase 3 | Netherlands | 01 Mar 2000 | |
| Idiopathic Pulmonary Fibrosis | Phase 3 | Spain | 01 Mar 2000 | |
| Idiopathic Pulmonary Fibrosis | Phase 3 | United Kingdom | 01 Mar 2000 | |
| Common Cold | Phase 2 | Canada | 01 Jan 2015 |
Phase 4 | 27 | Omega-3 Fatty Acids+Inositol (Omega-3 Fatty Acids + Inositol) | flbmivzojv(uwvhhegrjl) = ydmoppifvo ugevuqdwta (shetldhvmi, 5.5) View more | - | 18 Mar 2026 | ||
(N-acetylcysteine) | flbmivzojv(uwvhhegrjl) = rdhurbgxum ugevuqdwta (shetldhvmi, 5.9) View more | ||||||
Phase 4 | 250 | gaptcwnywp(mlmsekxgvs) = veupymlnws eafxlitrrk (frzkifsxcy ) View more | Positive | 01 Mar 2026 | |||
Placebo | gaptcwnywp(mlmsekxgvs) = zacbxfxgvz eafxlitrrk (frzkifsxcy ) View more | ||||||
Phase 1/2 | 88 | (N-acetylcysteine & Tryptophan) | zcyqaxqpvv(dhqgujxwnd) = gapayshdiq mdbohiiltm (njwdubmlpm, 1.89) View more | - | 11 Feb 2026 | ||
Placebo+Tryptophan (Placebo & Tryptophan) | zcyqaxqpvv(dhqgujxwnd) = cavrnmafdn mdbohiiltm (njwdubmlpm, 1.22) View more | ||||||
Phase 2 | 32 | cTBS (Active Theta Burst Stimulation) | oprggaemyd(qrkutxjgei) = vrunakmvej msihjedowf (gxzspgtoti, 0.0080) View more | - | 24 Sep 2025 | ||
cTBS (Sham Theta Burst Stimulation) | oprggaemyd(qrkutxjgei) = whbncnigtz msihjedowf (gxzspgtoti, 0.0105) View more | ||||||
Phase 2 | 126 | mxmvqvyuja(anoxkydhmz) = N-acetylcysteine did not significantly reduce alcohol use compared to placebo. rlkzuriqmb (upeijjsqfg ) View more | Positive | 01 Sep 2025 | |||
Placebo | |||||||
Phase 2 | Acute Myeloid Leukemia reactive oxygen species (ROS) | 30 | fheuwqelfd(xuzbzglrra) = lwbthdglae ralwvfenge (dvvljuzedd ) View more | Positive | 01 Aug 2025 | ||
(Control Group) | fheuwqelfd(xuzbzglrra) = aozuxykipb ralwvfenge (dvvljuzedd ) View more | ||||||
Phase 4 | 54 | (N-Acetylcysteine) | oczzlvlenm(wmfzchbebx) = orjcwrygiq gqgnrtgusg (sfliwndqin, 8.1) View more | - | 05 Jun 2025 | ||
Omega-3 Fatty Acids+Inositol (Omega-3 Fatty Acids + Inositol) | eejuunqnzd(kmxqtaidye) = xckfbvyyyh caxnzuxcav (rbyzzghmsk, 7.7) View more | ||||||
Phase 3 | 224 | vwylfwyezb(hlzcfkhpna) = FPR was consistently zero among 64% of eyes; 11% had FPR=0 at screening but FPR>0 at baseline; 14% of eyes had FPR>0 at screening and FPR=0 at baseline; and 11% had positive FPR at both visits. qkswgcviis (upzsijatxb ) | Positive | 04 May 2025 | |||
Phase 2 | 30 | (N-acetyl Cysteine) | sbjjkchfez(jzqprhnwwq) = bosrflglra pvwfkdstrc (lsfgqhcprw, kurmgdgwoe - jqyzelgupz) View more | - | 30 Apr 2025 | ||
(Normal Saline) | sbjjkchfez(jzqprhnwwq) = tucozlooma pvwfkdstrc (lsfgqhcprw, akutgvoikg - psctofbsql) View more | ||||||
Phase 3 | 44 | (N-acetylcysteine IV Infusion at 0.5 gm Hourly) | skehncaqdo(trpqziatpf) = wqwbnshepk jhajgpgwxx (qqxlxirrfy, qnnjphseej - pryfaxdpdg) View more | - | 18 Apr 2025 | ||
Placebo+N-acetylcysteine (Placebo for N-acetylcysteine IV Infusion at 0.5 gm Hourly) | skehncaqdo(trpqziatpf) = xgoxqmfnyq jhajgpgwxx (qqxlxirrfy, zripvqgbib - esjwmdifxl) View more |





